Houston, TX - May, 9, 2025 - OmniScience, the creator of Vivo - the first agentic AI clinical trial control tower - announces its acceptance into the NVIDIA Inception program. This prestigious global accelerator supports startups driving innovation in AI, deep learning, and data science.

OmniScience joins a curated network of cutting-edge companies and venture capital partners focused on advancing breakthrough technologies. Through NVIDIA Inception, the company will gain access to technical resources, go-to-market support, and a powerful ecosystem of collaborators across AI and healthcare.

“As we continue to scale Vivo and bring the power of agentic AI to clinical trials, being part of NVIDIA Inception is an exciting milestone,” said Colin Hendricks, CTO of OmniScience. “Access to NVIDIA’s deep expertise and expansive innovation network will help us accelerate the development of our platform and deliver greater value to sponsors, patients, and partners.”

Vivo is transforming the clinical development landscape by unifying fragmented data, providing real-time insights, and improving decision-making for clinical trials. Vivo empowers trial teams to reduce timelines, cut costs, and improve probability of success.

Acceptance into NVIDIA Inception reinforces OmniScience’s commitment to delivering transformative, high-impact AI technologies to the life sciences industry.